Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves part...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yang, Yu, Min, Li, Yanying, Zhou, Xiaojuan, Tian, Tian, Du, Yijia, Tu, Zegui, Huang, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437588/
https://www.ncbi.nlm.nih.gov/pubmed/36059688
http://dx.doi.org/10.3389/fonc.2022.945620
_version_ 1784781651677544448
author Yu, Yang
Yu, Min
Li, Yanying
Zhou, Xiaojuan
Tian, Tian
Du, Yijia
Tu, Zegui
Huang, Meijuan
author_facet Yu, Yang
Yu, Min
Li, Yanying
Zhou, Xiaojuan
Tian, Tian
Du, Yijia
Tu, Zegui
Huang, Meijuan
author_sort Yu, Yang
collection PubMed
description BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for BRAF fusions.
format Online
Article
Text
id pubmed-9437588
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94375882022-09-03 Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review Yu, Yang Yu, Min Li, Yanying Zhou, Xiaojuan Tian, Tian Du, Yijia Tu, Zegui Huang, Meijuan Front Oncol Oncology BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for BRAF fusions. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9437588/ /pubmed/36059688 http://dx.doi.org/10.3389/fonc.2022.945620 Text en Copyright © 2022 Yu, Yu, Li, Zhou, Tian, Du, Tu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yu, Yang
Yu, Min
Li, Yanying
Zhou, Xiaojuan
Tian, Tian
Du, Yijia
Tu, Zegui
Huang, Meijuan
Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title_full Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title_fullStr Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title_full_unstemmed Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title_short Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
title_sort rapid response to monotherapy with mek inhibitor trametinib for a lung adenocarcinoma patient harboring primary sdn1-braf fusion: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437588/
https://www.ncbi.nlm.nih.gov/pubmed/36059688
http://dx.doi.org/10.3389/fonc.2022.945620
work_keys_str_mv AT yuyang rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT yumin rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT liyanying rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT zhouxiaojuan rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT tiantian rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT duyijia rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT tuzegui rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview
AT huangmeijuan rapidresponsetomonotherapywithmekinhibitortrametinibforalungadenocarcinomapatientharboringprimarysdn1braffusionacasereportandliteraturereview

Ejemplares similares